In prostate cancer, inhibition of NMT1 also blocks the scaffold function of Src kinase and prevents protein–protein interaction with the androgen receptor (AR), thus inhibiting androgen-independent AR activation (Figure 1, 1). Here, AR is linked to prostate carcinoma.